A Leukemia Drug for Parkinson’s?
Two phase II nilotinib studies reach opposite conclusions
Related Articles
NEJM Gets Letter From DOJ
It’s the fourth journal to confirm receiving a letter asking about alleged bias
Antiviral Reduced Transmission of Influenza to Close Contacts
Baloxavir may have potential use in an influenza pandemic before a vaccine is developed
Healthcare Costs for Locally Advanced/Metastatic Urothelial Cancer
In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or metastatic urothelial carcinoma (la/mUC) is significant. Drug acquisition and…
Opinion | Could Trump’s War on Harvard Spell the End of U.S. Leadership in Science?
The stop-work orders I received were far more than just a personal loss
The Truth About Electrolytes, According to a Nephrologist
As summer approaches, Steven Fishbane, MD, talks about who needs more (or fewer) electrolytes
Opinion | Risk-Based Vaccination Strategies Can Build Back Public Trust
CDC’s advisory committee will vote on the updated COVID vaccine guidelines in June
U.S. Measles Cases Likely Underreported, CDC Says
Agency is ‘scraping’ to find resources to support Texas and southwestern states
The Intersection of Human Trafficking and Health Care – AJN Off the Charts
The health care encounter is an opportunity for nurses to disrupt the cycle of victimization by treating and responding to human trafficking victims, and by…
HHS Scraps Advisory Committee on Newborn Screening
Cut comes as new conditions could have been added to a national screening panel